|
1.
|
Shah SH, Jagannathan JP, Krajewski K,
O’Regan KN, George S and Ramaiya NH: Uterine sarcomas: then and
now. AJR Am J Roentgenol. 199:213–223. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
McCluggage WG: Malignant biphasic uterine
tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol.
55:321–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Schipf A, Mayr D, Kirchner T and Diebold
J: Molecular genetic aberrations of ovarian and uterine
carcinosarcomas - a CGH and FISH study. Virchows Arch. 452:259–268.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Mao XG, Yan M, Xue XY, Zhang X, Ren HG,
Guo G, Wang P, Zhang W and Huo JL: Overexpression of ZNF217 in
glioblastoma contributes to the maintenance of glioma stem cells
regulated by hypoxia-inducible factors. Lab Invest. 91:1068–1078.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Chiyoda T, Tsuda H, Tanaka H, Kataoka F,
Nomura H, Nishimura S, Takano M, Susumu N, Saya H and Aoki D:
Expression profiles of carcinosarcoma of the uterine corpus-are
these similar to carcinoma or sarcoma? Genes Chromosomes Cancer.
51:229–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Saegusa M, Hashimura M, Kuwata T and
Okayasu I: Requirement of the Akt/beta-catenin pathway for uterine
carcinosarcoma genesis, modulating E-cadherin expression through
the transactivation of slug. Am J Pathol. 174:2107–2115. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Nordal RR, Kristensen GB, Stenwig AE,
Tropé CG and Nesland JM: Immunohistochemical analysis of p53
protein in uterine sarcomas. Gynecol Oncol. 70:45–48. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Raspollini MR, Susini T, Amunni G,
Paglierani M, Castiglione F, Garbini F, Carriero C, Scarselli G and
Taddei GL: Expression and amplification of HER-2/neu oncogene in
uterine carcinosarcomas: a marker for potential molecularly
targeted treatment? Int J Gynecol Cancer. 16:416–422. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Huang GS, Arend RC, Li M, Gunter MJ, Chiu
LG, Horwitz SB and Goldberg GL: Tissue microarray analysis of
hormonal signaling pathways in uterine carcinosarcoma. Am J Obstet
Gynecol. 200:457.e1–5. 2009.PubMed/NCBI
|
|
10.
|
Resnick MB, Sabo E, Kondratev S, Kerner H,
Spagnoli GC and Yakirevich E: Cancer-testis antigen expression in
uterine malignancies with an emphasis on carcinosarcomas and
papillary serous carcinomas. Int J Cancer. 101:190–195. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Powell MA, Filiaci VL, Rose PG, Mannel RS,
Hanjani P, Degeest K, Miller BE, Susumu N and Ueland FR: Phase II
evaluation of paclitaxel and carboplatin in the treatment of
carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J
Clin Oncol. 28:2727–2731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kido A, Togashi K, Koyama T, Yamaoka T,
Fujiwara T and Fujii S: Diffusely enlarged uterus: evaluation with
MR imaging. Radiographics. 23:1423–1439. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mittal KR, Chen F, Wei JJ, Rijhvani K,
Kurvathi R, Streck D, Dermody J and Toruner GA: Molecular and
immunohistochemical evidence for the origin of uterine
leiomyosarcomas from associated leiomyoma and symplastic
leiomyoma-like areas. Mod Pathol. 22:1303–1311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Politi K, Szabolcs M, Fisher P, Kljuic A,
Ludwig T and Efstratiadis A: A mouse model of uterine
leiomyosarcoma. Am J Pathol. 164:325–336. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Skubitz KM and Skubitz AP: Differential
gene expression in leiomyosarcoma. Cancer. 98:1029–1038. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Yang J, Du X, Chen K, Ylipää A, Lazar AJ,
Trent J, Lev D, Pollock R, Hao X, Hunt K and Zhang W: Genetic
aberrations in soft tissue leiomyosarcoma. Cancer Lett. 275:1–8.
2009. View Article : Google Scholar
|
|
17.
|
Raspollini MR, Amunni G, Villanucci A,
Pinzani P, Simi L, Paglierani M and Taddei GL: c-Kit expression in
patients with uterine leiomyosarcomas: a potential alternative
therapeutic treatment. Clin Cancer Res. 10:3500–3503. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
D’Angelo E and Prat J: Uterine sarcomas: a
review. Gynecol Oncol. 116:131–139. 2010.
|
|
19.
|
Kefeli M, Yildiz L, Kaya FC, Aydin O and
Kandemir B: Fascin expression in uterine smooth muscle tumors. Int
J Gynecol Pathol. 28:328–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Koivisto-Korander R, Butzow R, Koivisto AM
and Leminen A: Immunohistochemical studies on uterine
carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma:
expression and prognostic importance of ten different markers.
Tumour Biol. 32:451–459. 2011. View Article : Google Scholar
|
|
21.
|
Dhingra S, Rodriguez ME, Shen Q, Duan X,
Stanton ML, Chen L, Zhang R and Brown RE: Constitutive activation
with overexpression of the mTORC2-phospholipase D1 pathway in
uterine leiomyosarcoma and STUMP: morphoproteomic analysis with
therapeutic implications. Int J Clin Exp Pathol. 4:134–146.
2010.
|
|
22.
|
Xing D, Scangas G, Nitta M, He L, Xu X,
Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY,
Mohapatra G and Orsulic S: A role for BRCA1 in uterine
leiomyosarcoma. Cancer Res. 69:8231–8235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hayashi T, Horiuchi A, Sano K, Hiraoka N,
Kasai M, Ichimura T, Nagase S, Ishiko O, Shiozawa T, Kanai Y,
Yaegashi N, Aburatani H, Tonegawa S and Konishi I: Involvement of
proteasome β1i subunit, LMP2, on development of uterin
leiomyosarcma. N Am J Med Sci. 3:394–399. 2011.
|
|
24.
|
Hensley ML, Blessing JA, Mannel R and Rose
PG: Fixed-dose rate gemcitabine plus docetaxel as first-line
therapy for metastatic uterine leiomyosarcoma: a Gynecologic
Oncology Group phase II trial. Gynecol Oncol. 109:329–334. 2008.
View Article : Google Scholar
|
|
25.
|
Hensley ML, Sill MW, Scribner DR Jr, Brown
J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR and Gehrig
PA: Sunitinib malate in the treatment of recurrent or persistent
uterine leiomyosarcoma: a Gynecologic Oncology Group phase II
study. Gynecol Oncol. 115:460–465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M,
Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD,
Dei Tos AP and Hohenberger P; EORTC Soft Tissue and Bone Sarcoma
Group; PALETTE study group: Pazopanib for metastatic soft-tissue
sarcoma (PALETTE): a randomised, double-blind, placebo-controlled
phase 3 trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI
|
|
27.
|
Ng JS, Han A, Chew SH and Low J: A
clinicopathologic study of uterine smooth muscle tumours of
uncertain malignant potential (STUMP). Ann Acad Med Singapore.
39:625–628. 2010.PubMed/NCBI
|
|
28.
|
Ünver NU, Acikalin MF, Öner Ü, Ciftci E,
Ozalp SS and Colak E: Differential expression of P16 and P21 in
benign and malignant uterine smooth muscle tumors. Arch Gynecol
Obstet. 284:483–490. 2011.PubMed/NCBI
|
|
29.
|
Chen L and Yang B: Immunohistochemical
analysis of p16, p53, and Ki-67 expression in uterine smooth muscle
tumors. Int J Gynecol Pathol. 27:326–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Atkins KA, Arronte N, Darus CJ and Rice
LW: The use of p16 in enhancing the histologic classification of
uterine smooth muscle tumors. Am J Surg Pathol. 32:98–102. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Koyama T, Togashi K, Konishi I, Kobayashi
H, Ueda H, Kataoka ML, Kobayashi H, Itoh T, Higuchi T, Fujii S and
Konishi J: MR imaging of endometrial stromal sarcoma: correlation
with pathologic findings. Am J Roentgenol. 173:767–772. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Jung CK, Jung JH, Lee A, Lee YS, Choi YJ,
Yoon SK and Lee KY: Diagnostic use of nuclear beta-catenin
expression for the assessment of endometrial stromal tumors. Mod
Pathol. 21:756–763. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hrzenjak A, Moinfar F, Tavassoli FA,
Strohmeier B, Kremser ML, Zatloukal K and Denk H: JAZF1/JJAZ1 gene
fusion in endometrial stromal sarcomas: molecular analysis by
reverse transcriptase-polymerase chain reaction optimized for
paraffin-embedded tissue. J Mol Diagn. 7:388–395. 2005. View Article : Google Scholar
|
|
34.
|
Micci F, Panagopoulos I, Bjerkehagen B and
Heim S: Consistent rearrangement of chromosomal band 6p21 with
generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial
stromal sarcoma. Cancer Res. 66:107–112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Panagopoulos I, Micci F, Thorsen J,
Gorunova L, Eibak AM, Bjerkehagen B, Davidson B and Heim S: Novel
fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial
stromal sarcoma. PLoS One. 7:e393542012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Lee CH, Ou WB, Mariño-Enriquez A, Zhu M,
Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB,
McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPherson A, Jones
SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P,
Debiec-Rychter M, Nucci MR and Fletcher JA: 14-3-3 fusion oncogenes
in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA.
109:929–934. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Kaku T, Silverberg SG, Major FJ, Miller A,
Fetter B and Brady MF: Adenosarcoma of the uterus: a Gynecologic
Oncology Group clinicopathologic study of 31 cases. Int J Gynecol
Pathol. 11:75–88. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Chourmouzi D, Boulogianni G, Zarampoukas T
and Drevelengas A: Sonography and MRI of tamoxifen-associated
müllerian adenosarcoma of the uterus. Am J Roentgenol.
181:1673–1675. 2003.PubMed/NCBI
|
|
39.
|
Amant F, Steenkiste E, Schurmans K,
Verbist L, Abeler VM, Tulunay G, de Jonge E, Massuger L, Moerman P
and Vergote I: Immunohistochemical expression of CD10 antigen in
uterine adenosarcoma. Int J Gynecol Cancer. 14:1118–1121. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Tesfaye A, Di Cello F, Hillion J, Ronnett
BM, Elbahloul O, Ashfaq R, Dhara S, Prochownik E, Tworkoski K,
Reeves R, Roden R, Ellenson LH, Huso DL and Resar LM: The
high-mobility group A1 gene up-regulates cyclooxygenase 2
expression in uterine tumorigenesis. Cancer Res. 67:3998–4004.
2007. View Article : Google Scholar : PubMed/NCBI
|
